NCT04609176招募中2 期
A Prospective, Non-randomized, Multicenter, Phase II Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Unresectable Recurrent or Metastatic Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Peking University1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2020年11月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment
研究概览
简要总结
This is a study of Camrelizumab (SHR-1210) and Apatinb for unresectable Recurrent or metastatic alpha-fetoprotein (AFP)-producing gastric cancer or Gastroesophageal Junction Adenocarcinoma. Camrelizumab combined with Apatinib and standard chemotherapy will be given to treatment-naïve participants; Camrelizumab combined with Apatinib will also be evaluated in participants who have had ≥ 1 line of previous treatment. The primary endpoint is the Overall Response Rate (ORR).
详细描述
This study will have 2 cohorts. In Cohort 1, participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. In Cohort 2, participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. A Simon two-stage phase II design was used for the sample size Calculation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who provided written informed consent to be subjects in this trial
- •Aged ≥18 years
- •Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
- •Has histologically-confirmed diagnosis of locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma
- •Clinical staging was performed according to enhanced CT/MRI examination (combined with endoscopic ultrasonography and diagnostic laparoscopic exploration if necessary). For patients with locally advanced or metastatic gastric/GEJ cancer in stage III-IV (AJCC 8 edition TNM stage) that could not be resected, the possibility of resectable was determined by MDT
- •For cohort 1, no prior systemic chemotherapy for the treatment of the participant's advanced or metastatic disease (treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior to the diagnosis of advanced or metastatic disease); for cohort 2, received and progressed on ≥1 prior systemic therapy for their advanced disease.
- •Have measurable disease as defined by RECIST 1.1 as determined by investigator assessment
- •Serum AFP > 2 upper limit of normal (ULN) or AFP positive by immunohistochemical staining methods
- •Adequate Organ Function Laboratory Values:
- •Hemoglobin ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×109/L; Platelets ≥80×109/L; AST and ALT ≤ 2.5 ULN or ≤ 5 ULN for subjects with liver metastases; Total bilirubin ≤1.5 ULN; Serum creatinine ≤1.5 ULN or measured or calculated creatinine clearance > 50ml/min; Albumin ≥ 30g/L;
- •No serious concomitant disease result in survival of less than 5 years
- •Patients capable of taking oral medication
- •Have good compliance and be able to follow the study protocol
- •Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication and must be willing to use an adequate method of contraception for the course of the study through 90 days after the last dose of study medication. Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy
- •Agree to provide blood and/or tumor tissue sample deemed adequate for PD-L1 and other biomarker analysis.
排除标准
- •Is pregnant or breastfeeding
- •HER2 positive subjects will be excluded from cohort 1
- •Patients have recovered adverse events associated with pretreatment to Grade 1 or lower with CTCAE v5.0 excluding alopecia
- •Patients have an active malignancy (except for definitively treated basal cell carcinoma of the skin, or carcinoma-in-situ of the cervix) within the past 5 years
- •Active heart disease that is not well controlled, e.g. symptomatic coronary heart disease, New York Heart Association (NYHA) congestive heart failure of grade II or above, severe arrhythmias requiring drug intervention, myocardial infarction within the past 12 months, QTc ≥ 450ms for male, QTc ≥ 450ms for female, LVEF<50%
- •Genetic or acquired bleeding and thrombotic tendencies (e.g., hemophilia, coagulation disorders, thrombocytopenia, etc.)
- •Patients with a history of gastrointestinal perforation, intra-abdominal abscess, or in-three-months ileus
- •Coagulation disorders (International normalized ratio, INR > 2.0 or Prothrombin time, PT > 16s)
- •Organ transplantation requires immunosuppressants, or who have received immunosuppressants/systemic corticosteroids therapy <14 days before first dose for an immunosuppression purpose (> 10mg/day prednisone or other equivalency drugs)
- •Patients have an active ulcer, serious non-healing wound, or bone fracture
- •Patients with hypertension that is difficult to control (systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg) despite treatment with several hypotensive agents
- •Patients have a deficiency of dihydropyrimidine dehydrogenase (DPD) will be excluded from cohort 1
- •Have any contraindications for study treatment
- •Patients with a history of prior treatment with Apatinib or any anti-PD-1, anti-PD-L1 agent
- •Urinary protein is more than 2+ and 24-hour urine protein > 1.0g
- •Patients with active hepatitis B (HBsAg positive and HBV DNA≥500 IU/ml), hepatitis C (HCV antibodies positive and HCV RNA copies > ULN); with active infection requiring drug intervention
- •Patients with active symptoms or signs of interstitial lung disease
- •Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease
- •Patients were judged unsuitable as subjects of this trial by investigators.
研究组 & 干预措施
Camrelizumab+Apatinib+SOX
Experimental
Participants who have not received any previous therapy for their disease will receive Camrelizumab and Apatinib in combination with Oxaliplatin and S-1. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.
干预措施: Camrelizumab plus Apatinib and SOX (Drug)
Camrelizumab+Apatinib
Experimental
Participants who have received at least one prior therapy for their advanced disease will receive Camrelizumab and Apatinib. Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
干预措施: Camrelizumab plus Apatinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR) According to RECIST 1.1 based on investigator assessment
时间窗: Up to approximately 24 months
ORR was defined as the percentage of the participants in the analysis population who had a confirmed CR or PR according to RECIST 1.1 based on investigator assessment.
次要结局
- Duration of Response (DOR) According to iRECIST 1.1 base on investigator assessment(Up to approximately 24 months)
- Overall Survival (OS)(Up to approximately 24 months)
- Number of Participants Experiencing an Adverse Event (AE)(Up to approximately 27 months)
- Progression-free Survival (PFS) According to RECIST 1.1 base on investigator assessment(Up to approximately 24 months)
- Duration of Response (DOR) According to RECIST 1.1 Based on investigator assessment(Up to approximately 24 months)
- Progression-free Survival (PFS) According to iRECIST 1.1 base on investigator assessment(Up to approximately 24 months)
- Objective Response Rate (ORR) According to iRECIST 1.1 based on investigator assessment(Up to approximately 24 months)
- Disease Control Rate (DCR) According to RECIST 1.1 based on investigator assessment(Up to approximately 24 months)
- Disease Control Rate (DCR) According to iRECIST 1.1 base on investigator assessment(Up to approximately 24 months)
研究者
Shen Lin
Professor
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerSmall Cell Lung CarcinomaNCT04901754Henan Cancer Hospital38
进行中（未招募）
2 期
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureRecurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal CarcinomaChemotherapy EffectImmunotherapyMolecular Targeted TherapyNasopharyngeal CarcinomaNCT04586088Sun Yat-sen University58
Unknown
2 期
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCHead and Neck Squamous Cell CarcinomaNCT04399785Xingchen Peng34
尚未招募
2 期
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNSCLCNCT04506242Cancer Institute and Hospital, Chinese Academy of Medical Sciences74
已完成
2 期
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaResectable Hepatocellular CarcinomaNCT04701060Tianjin Medical University Cancer Institute and Hospital31